Italia markets closed

CNTB Jun 2024 2.500 put

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
1,00000,0000 (0,00%)
Alla chiusura: 11:25AM EDT
Schermo intero
Chiusura precedente1,0000
Aperto1,0000
Denaro0,0000
Domanda2,5000
Prezzo d'esercizio2,50
Scadenza2024-06-21
Min-Max giorno1,0000 - 1,0000
Contratto - Min-MaxN/D
Volume1
Open Interest1
  • GlobeNewswire

    Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update

    Key data readouts with Company’s lead drug candidate rademikibart expected in the fourth quarter of 2023 Topline results from Stage 2 of the China pivotal trial in atopic dermatitisTopline results from Global Phase 2 trial in asthma Cash balance of $131.6 million expected to support planned operations into at least 2026 SAN DIEGO and TAICANG, China, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage

  • GlobeNewswire

    Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

    SAN DIEGO and TAICANG, China, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today that on September 11, 2023, it received a letter from the Listings Qualifications Department of the Nasdaq Stock Market LLC (

  • GlobeNewswire

    Connect Biopharma to Participate in Upcoming September Investor Conferences

    SAN DIEGO and TAICANG, China, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that Connect Biopharma’s management team will participate at the following upcoming investor conferences: H.C. Wainwright 25th